Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy.
Teisseyre M, Cremoni M, Boyer-Suavet S, Crepin T, Benzaken S, Zorzi K, Esnault V, Brglez V, Seitz-Polski B. Teisseyre M, et al. Among authors: boyer suavet s. Front Immunol. 2021 Oct 13;12:738788. doi: 10.3389/fimmu.2021.738788. eCollection 2021. Front Immunol. 2021. PMID: 34721403 Free PMC article.
Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults.
Barbour T, Scully M, Ariceta G, Cataland S, Garlo K, Heyne N, Luque Y, Menne J, Miyakawa Y, Yoon SS, Kavanagh D; 311 Study Group Members. Barbour T, et al. Kidney Int Rep. 2021 Mar 24;6(6):1603-1613. doi: 10.1016/j.ekir.2021.03.884. eCollection 2021 Jun. Kidney Int Rep. 2021. PMID: 34169200 Free PMC article.
Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296.
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H; 311 Study Group. Rondeau E, et al. Kidney Int. 2021 May;99(5):1244. doi: 10.1016/j.kint.2021.03.008. Kidney Int. 2021. PMID: 33892867 No abstract available.
Proteinuria as a Biomarker for COVID-19 Severity.
Ouahmi H, Courjon J, Morand L, François J, Bruckert V, Lombardi R, Esnault V, Seitz-Polski B, Demonchy E, Dellamonica J, Boyer-Suavet S. Ouahmi H, et al. Among authors: boyer suavet s. Front Physiol. 2021 Mar 9;12:611772. doi: 10.3389/fphys.2021.611772. eCollection 2021. Front Physiol. 2021. PMID: 33767630 Free PMC article.
Humoral and Cellular Response of Frontline Health Care Workers Infected by SARS-CoV-2 in Nice, France: A Prospective Single-Center Cohort Study.
Cremoni M, Ruetsch C, Zorzi K, Fernandez C, Boyer-Suavet S, Benzaken S, Demonchy E, Dellamonica J, Ichai C, Esnault V, Brglez V, Seitz-Polski B. Cremoni M, et al. Among authors: boyer suavet s. Front Med (Lausanne). 2021 Jan 27;7:608804. doi: 10.3389/fmed.2020.608804. eCollection 2020. Front Med (Lausanne). 2021. PMID: 33585509 Free PMC article.
Functional Exhaustion of Type I and II Interferons Production in Severe COVID-19 Patients.
Ruetsch C, Brglez V, Crémoni M, Zorzi K, Fernandez C, Boyer-Suavet S, Benzaken S, Demonchy E, Risso K, Courjon J, Cua E, Ichai C, Dellamonica J, Passeron T, Seitz-Polski B. Ruetsch C, et al. Among authors: boyer suavet s. Front Med (Lausanne). 2021 Jan 27;7:603961. doi: 10.3389/fmed.2020.603961. eCollection 2020. Front Med (Lausanne). 2021. PMID: 33585507 Free PMC article.
20 results